The Journal of the American Academy of Dermatology published a response letter on October 12, 2026, addressing methodological questions raised about skin cancer risk in systemic sclerosis patients who receive transplants.

Authors Ruhi Kanwar and Vinod E. Nambudiri wrote the reply to Xie et al., whose original correspondence was titled "Methodological Considerations and Clinical Implications for Skin Cancer Risk in Systemic Sclerosis Transplant Recipients." The exchange appeared online on October 12, 2026, JAAD's publication record shows.

Why does this exchange matter?

Correspondence in JAAD typically targets how a study was built — cohort definition, confounder control, and how exposure to immunosuppression gets measured — before it targets the conclusion. That pattern fits here. The Xie et al. letter explicitly frames its critique around "methodological considerations," and the reply from Kanwar and Nambudiri engages those points directly.

The clinical stakes are concrete. Systemic sclerosis patients who undergo transplantation face long-term immunosuppression, a known driver of cutaneous malignancy risk, so how a study measures that risk shapes surveillance advice dermatologists give this cohort. A methodological dispute over confounders or denominator choice can move the apparent risk estimate enough to change screening intervals or patient counseling.

What the reply covers

The published record confirms these basics:

• Publication venue: Journal of the American Academy of Dermatology, available online October 12, 2026.
• Authors of the response: Ruhi Kanwar and Vinod E. Nambudiri.
• Target of the reply: Xie et al.'s letter on methodological considerations and clinical implications for skin cancer risk in systemic sclerosis transplant recipients.
• Format: Correspondence — a response letter, not an original research article.

The full text of the Kanwar–Nambudiri reply, including any point-by-point rebuttal of the methodological critiques, sits behind JAAD's online edition. Readers tracking this exchange should pair the response with the original Xie et al. letter to judge whose framing of the risk data holds up.

What comes next

Correspondence threads like this one often seed revised analyses or secondary studies of the same transplant registry data. Whether Kanwar and Nambudiri's reply prompts a formal reanalysis, dermatologists following cutaneous malignancy surveillance in systemic sclerosis will find the exchange in JAAD's online edition as of October 12, 2026.